Is CytoDyn Inc (CYDY) a Stock to Watch After Gaining 11.11% This Week?

CytoDyn Inc (CYDY) stock has gained 11.11% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

CytoDyn Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CYDY!

See Full CYDY Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CYDY Stock Today?

CytoDyn Inc (CYDY) stock is trading at $0.40 as of 12:43 PM on Tuesday, Jun 28, a loss of -$0.04, or -9.09% from the previous closing price of $0.44. The stock has traded between $0.40 and $0.43 so far today. Volume today is light. So far 466,340 shares have traded compared to average volume of 1,520,383 shares. To see InvestorsObserver's Sentiment Score for CytoDyn Inc click here.

More About CytoDyn Inc

CytoDyn Inc is a US-based clinical-stage biotechnology company which focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes on exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer. Click Here to get the full Stock Report for CytoDyn Inc stock.